FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

NATCOPHARM Share Price Discussion

Natco Pharma Ltd.
NSE: NATCOPHARM | BSE: 524816 | ISIN: INE987B01026 | Sector: Pharmaceuticals and health care

NATCOPHARM Rating

3.8/5 (8 Ratings)
NATCOPHARM Share Price *
675 +1.05 (0.16%)
* (quote may be delayed)
Find answers to all your questions on live NATCOPHARM message board: Is NATCOPHARM buy or sell? Should I buy NATCOPHARM shares? Why are NATCOPHARM shares falling? Should I invest in NATCOPHARM stock?

You can also check NATCOPHARM share price target recommended by brokerages.

NATCOPHARM Discussion Forum

@newsbot • Reputation: 2,292
Natco Pharma Q3 net profit declines 34% to Rs 104.4cr
Consolidated total income stood at Rs 513 crore for the quarter under consideration. It was Rs 580 crore for the same period a year ago.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enter Consolidated December 2019 Net Sales at Rs 3,805.67 crore, up 9.07% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises Q3 profit surges 20% to Rs 724cr
Revenue from operations also rose to Rs 3,805.67 crore for the quarter under review as against Rs 3,489.30 crore in the year-ago period.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises share price gains 7% on robust Q3 results
Revenue of the company was up 9.1 percent at Rs 3,806 crore versus Rs 3,489 crore, YoY.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Market Headstart: Nifty likely to head towards 11,750; All eyes on Airtel, PNB earnings
Trends on SGX Nifty indicate a positive opening for the index in India, with a 45 points, or 0.39 percent, gain
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Hot Stocks | Short-term trend for Nifty bearish; sell Piramal Ent, Indiabulls Housing
Last week’s fall has led to Nifty reversing its uptrend as it closed below the trend reversal levels of 11,832 and the index formed a big red candle on the weekly charts.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises eyeing $500 mn fund raise; appoints Rothschild for pharma stake sale
The pharma segment contributed Rs 4,786 crores or 36% of the group’s revenues of Rs 13215 crores in FY19.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal's contract research arm to invest 25 million Canadian dollars to expand Aurora facility
The additional capacity will cater to increasing customer demand.
Moneycontrol
Like
reply
Reply
@tipupahan • Reputation: -2,195

Natcopharma buy above 620, sl – 614, tgt – 632
Like
reply
Reply (1)
Latest replies
Tipu Pahan @tipupahan
Jan 2 2:58 PM

TARGET DONE... 12 POINTS DONE.
@TTA • Reputation: 9,205

Natco Pharma-2QFY20 Result Update-13 November 2019.pdf
468 KB
Natco Pharma
Domestic Sales Disappoint
Like
reply
Reply

NATCO PHARMA LTD : JEFFERIES CUTS PRICE TARGET TO 750 RUPEES FROM 850 RUPEES; RATING BUY
1
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises to raise Rs 5,400cr via rights, preferential debt issues
The preferential allotment will take place by November this year and the rights issue is expected to be completed by February 2020, it added.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises tanks 15%; board approves fresh capital raise of Rs 5,400 cr
The stock witnessed spurt in volume by more than 1.13 times and saw fall in share price to the tune of 40 percent in the last six months.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enter Consolidated September 2019 Net Sales at Rs 3,603.56 crore, up 14.61% Y-o-Y
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises dispels rumours about financial biz, files complaint with Sebi
Certain market participants are spreading false/misleading rumours against the company's financial services business in an attempt to create panic among various stakeholders, it said in a regulatory filing.
Moneycontrol
Like
reply
Reply
@TTA • Reputation: 9,205

NATCO PHARMA: CO RECEIVES ESTABLISHMENT INSPECTION REPORT FOR MEKAGUDA'S ACTIVE PHARMACEUTICAL INGREDIENT FACILITY
Like
reply
Reply
@newsbot • Reputation: 2,292
Natco Pharma gets EIR from USFDA for Hyderabad facility
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Brokerages initiate coverage on these 8 stocks in September, expect 13-52% return
The market is likely to remain in a tight range due to lack of domestic triggers as well as mixed global cues," Siddhartha Khemka, Head - Retail Research at MOFSL told Moneycontrol.
Moneycontrol
Like
reply
Reply
@farid • Reputation: 0

Sell natcopharma below 566 cmp 576 tgt open
For sure call what's app me on 7276280387
Like
reply
Reply

BUYYYYYYYYYYYYYYYYYYYY Natco Pharma 565/- sl 558 tr 580/-590
Like
reply
Reply
@newsbot • Reputation: 2,292
Rupee headwinds will put pressure on equities; could retest Rs 74/$ in near term
Rupee successfully retested its multi-year breakout zone of 69 and is poised to retest its previous zone of Rs 74.5/$ and could even breach it
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises slips 3% after board defers NCD issue
The share touched its 52-week high Rs 3,302.55 and 52-week low Rs 1,651.80 on 31 August, 2018 and 07 August, 2019, respectively.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,292
Hold Natco Pharma; target of Rs 595: ICICI Direct
ICICI Direct recommended hold rating on Natco Pharma with a target price of Rs 595 in its research report dated August 12, 2019.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Stocks in the news: RIL, Tata Motors, ONGC, BHEL, BPCL, Sintex Plastics, Varroc Engg, Oil India
Tata Motors | Alembic | Bosch | National Aluminium Company | Unichem Laboratories | ONGC | BHEL | BPCL and Sintex Plastics are among stocks, which are in news today.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Natco Pharma gets EIR from USFDA for Kothur facility
The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company’s drug formulations facility in Kothur, Natco Pharma said in a BSE filing.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Buy Piramal Enterprises; target of Rs 2400: Motilal Oswal
Motilal Oswal is bullish on Piramal Enterprises has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated July 30, 2019.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Pfizer’s Upjohn-Mylan merger may have little impact on India operations
As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enterprises Q1 net up 21% at Rs 461 cr
Net sales rose 21 per cent to Rs 3,506 crore in the latest quarter as against Rs 2,902 crore in June quarter 2018-19, Piramal Enterprises said in a statement.
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enter Consolidated June 2019 Net Sales at Rs 3,506.25 crore, up 20.8% Y-o-Y
www.moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Enter Standalone June 2019 Net Sales at Rs 871.98 crore, up 0.98% Y-o-Y
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Piramal Capital eyes buyouts worth $600m in NBFC space; targets DHFL’s porfolio: Report
In June, Piramal Enterprises sold its entire stake (nearly 10 percent) in Shriram Transport Finance to institutional investors for Rs 2,300 crore
moneycontrol.com
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
@newsbot • Reputation: 2,292
Like
reply
Reply
  • NATCOPHARM - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization13,915.91
    Enterprise Value13,916.81
    Price to Earnings19.94
    Price to Book Value4.45
    Return on Capital Employed0.27
    Return on Equity0.22
    Face Value2
    Dividend Yield0.01
  • NATCOPHARM Share Price - Technicals

    keyboard_arrow_down
    NATCOPHARM - 52 Week High₹738.1
    NATCOPHARM - 52 Week Low₹480
  • NATCOPHARM - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    13-Aug-19Nirmal BangBuy654
    9-Aug-19AnandRathiBuy763
    31-May-19Geojit Financial ServicesSell487
    29-May-19ICICIdirect.comHold595
    29-May-19Nirmal BangBuy654
    NATCOPHARM Brokerage Price Target
  • NATCOPHARM Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Feb 14675684.3668.2676.6
    Feb 13670677.6655673.95
    Feb 12711.05717690.2708.75
    Feb 11720724701.3715.45
    Feb 10711.05738.1695.1717.65
  • NATCOPHARM Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹660.41
    30 Day Moving Average₹646.05
    50 Day Moving Average₹622.04
    100 Day Moving Average₹598.4
    200 Day Moving Average₹567.14
  • NATCOPHARM - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,0912,002.80.04
    Operating Profit9286920.34
    Profit Before Tax888634.10.4
    Net Income698494.80.41
  • NATCOPHARM - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds3,1261,699.70.84
    Total Liabilities612648.4-0.06
    Total Assets3,7372,348.10.59
  • NATCOPHARM - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity476329.80.44
    Cash from Investing Activity-1,131-290.62.89
    Cash from Financing Activity652-170.2-4.83
    Net Cash Flow-3-131-0.98
  • NATCOPHARM - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.190.21
    Return on Equity0.220.29
    Return on Capital Employed0.270.34
  • NATCOPHARM - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue1.92
    3 Year CAGR Growth in Operating Profit3.35
    3 Year CAGR Growth in EBIDTA3.26
    3 Year CAGR Growth in Net Income3.56
    3 Yr CAGR Growth - Diluted EPS-0.18
  • NATCOPHARM - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.75
    5 Year CAGR Growth in Operating Profit5.39
    5 Year CAGR Growth in EBIDTA5.15
    5 Year CAGR Growth in Net Income7.93
    3 Yr CAGR Growth - Diluted EPS0.52
  • NATCOPHARM - Recent News

    keyboard_arrow_down
    NewsBot
    Feb 13 12:13 AM
    Natco Pharma Q3 net profit declines 34% to Rs 104.4cr
    Moneycontrol
    NewsBot
    Feb 5 3:08 PM
    Piramal Enter Consolidated December 2019 Net Sales at Rs 3,805.67 crore, up 9.07% Y-o-Y
    Moneycontrol
    NewsBot
    Feb 4 7:43 PM
    Piramal Enterprises Q3 profit surges 20% to Rs 724cr
    Moneycontrol
    NewsBot
    Feb 4 6:43 PM
    Piramal Enterprises share price gains 7% on robust Q3 results
    Moneycontrol
    NewsBot
    Feb 4 2:18 PM
    Market Headstart: Nifty likely to head towards 11,750; All eyes on Airtel, PNB earnings
    Moneycontrol
    NewsBot
    Feb 4 1:58 PM
    Hot Stocks | Short-term trend for Nifty bearish; sell Piramal Ent, Indiabulls Housing
    Moneycontrol
    NewsBot
    Jan 28 8:58 PM
    Piramal Enterprises eyeing $500 mn fund raise; appoints Rothschild for pharma stake sale
    Moneycontrol
    NewsBot
    Jan 28 7:38 PM
    Piramal's contract research arm to invest 25 million Canadian dollars to expand Aurora facility
    Moneycontrol
    NewsBot
    Oct 25 8:33 PM
    Piramal Enterprises to raise Rs 5,400cr via rights, preferential debt issues
    Moneycontrol
    NewsBot
    Oct 25 6:53 PM
    Piramal Enterprises tanks 15%; board approves fresh capital raise of Rs 5,400 cr
    Moneycontrol
  • NATCOPHARM - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Glenmark Pharmaceuticals Ltd. Sector...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.